Rare driver mutations: BRAF- and HER2-mutant NSCLC
Rare driver mutations: BRAF- and HER2-mutant NSC
ALK-positive NSCLC: updates on crizotinib and alectinib
ALK-positive NSCLC: updates on crizotinib and al
Characteristics and outcomes for SCLC arising from transformation
Characteristics and outcomes for SCLC arising fr
Reaching unprecedented outcome dimensions in malignant mesothelioma
Reaching unprecedented outcome dimensions in mal
Interview: “Survival is the result of multiple treatment lines”
Interview: “Survival is the result of multiple t
EGFR-mutant lung cancer: sequencing as a major topic in light of new data
EGFR-mutant lung cancer: sequencing as a major t
Randomised findings on CT-based follow-up after resection of early NSCLC
Randomised findings on CT-based follow-up after
Immunostimulation as a promising approach in SCLC
Immunostimulation as a promising approach in SCL
Immunotherapy: once more at the cutting edge of progress
Immunotherapy: once more at the cutting edge of
Preface – ESMO 2017
Preface – ESMO 2017 David R. Gandara, MD Pro
